Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.67
NYSE:RMD's Cash-to-Debt is ranked lower than
62% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.46 vs. NYSE:RMD: 0.67 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:RMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33  Med: 2.34 Max: No Debt
Current: 0.67
Equity-to-Asset 0.52
NYSE:RMD's Equity-to-Asset is ranked lower than
63% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NYSE:RMD: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:RMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.74 Max: 0.86
Current: 0.52
0.34
0.86
Interest Coverage 56.68
NYSE:RMD's Interest Coverage is ranked higher than
53% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.78 vs. NYSE:RMD: 56.68 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:RMD' s Interest Coverage Range Over the Past 10 Years
Min: 38.28  Med: 111.33 Max: No Debt
Current: 56.68
Piotroski F-Score: 4
Altman Z-Score: 6.07
Beneish M-Score: -2.40
WACC vs ROIC
7.52%
18.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 21.03
NYSE:RMD's Operating Margin % is ranked higher than
87% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.41 vs. NYSE:RMD: 21.03 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:RMD' s Operating Margin % Range Over the Past 10 Years
Min: 12.59  Med: 21.76 Max: 26.05
Current: 21.03
12.59
26.05
Net Margin % 16.99
NYSE:RMD's Net Margin % is ranked higher than
89% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. NYSE:RMD: 16.99 )
Ranked among companies with meaningful Net Margin % only.
NYSE:RMD' s Net Margin % Range Over the Past 10 Years
Min: 9.26  Med: 18.44 Max: 22.2
Current: 16.99
9.26
22.2
ROE % 19.96
NYSE:RMD's ROE % is ranked higher than
88% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. NYSE:RMD: 19.96 )
Ranked among companies with meaningful ROE % only.
NYSE:RMD' s ROE % Range Over the Past 10 Years
Min: 7.94  Med: 15.55 Max: 21.47
Current: 19.96
7.94
21.47
ROA % 11.46
NYSE:RMD's ROA % is ranked higher than
85% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. NYSE:RMD: 11.46 )
Ranked among companies with meaningful ROA % only.
NYSE:RMD' s ROA % Range Over the Past 10 Years
Min: 5.87  Med: 12.21 Max: 15.54
Current: 11.46
5.87
15.54
ROC (Joel Greenblatt) % 57.24
NYSE:RMD's ROC (Joel Greenblatt) % is ranked higher than
88% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. NYSE:RMD: 57.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:RMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 19.19  Med: 42.13 Max: 58.32
Current: 57.24
19.19
58.32
3-Year Revenue Growth Rate 7.90
NYSE:RMD's 3-Year Revenue Growth Rate is ranked higher than
65% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. NYSE:RMD: 7.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:RMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.9  Med: 23.2 Max: 30.4
Current: 7.9
7.9
30.4
3-Year EBITDA Growth Rate 5.80
NYSE:RMD's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. NYSE:RMD: 5.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:RMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 5.8  Med: 19.3 Max: 48.6
Current: 5.8
5.8
48.6
3-Year EPS without NRI Growth Rate 5.80
NYSE:RMD's 3-Year EPS without NRI Growth Rate is ranked lower than
52% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.50 vs. NYSE:RMD: 5.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:RMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 19.5 Max: 66.7
Current: 5.8
0
66.7
GuruFocus has detected 4 Warning Signs with ResMed Inc $NYSE:RMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:RMD's 10-Y Financials

Financials (Next Earnings Date: 2017-04-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RMD Guru Trades in Q1 2016

Steven Cohen 332,200 sh (New)
Joel Greenblatt 112,449 sh (New)
Ray Dalio 49,576 sh (New)
Paul Tudor Jones 17,831 sh (+95.95%)
Ken Fisher 20,950 sh (+10.12%)
Jim Simons 1,283,100 sh (+1.34%)
Jeremy Grantham Sold Out
George Soros Sold Out
John Hussman 2,300 sh (-95.40%)
» More
Q2 2016

RMD Guru Trades in Q2 2016

Columbia Wanger 1,045,999 sh (New)
Joel Greenblatt 262,958 sh (+133.85%)
John Hussman 2,300 sh (unchged)
Ken Fisher 20,950 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Jim Simons 788,700 sh (-38.53%)
Paul Tudor Jones 8,245 sh (-53.76%)
» More
Q3 2016

RMD Guru Trades in Q3 2016

Paul Tudor Jones 17,487 sh (+112.09%)
Jim Simons 1,421,600 sh (+80.25%)
Joel Greenblatt 296,383 sh (+12.71%)
John Hussman 2,300 sh (unchged)
Ken Fisher 20,950 sh (unchged)
Columbia Wanger 1,023,346 sh (-2.17%)
» More
Q4 2016

RMD Guru Trades in Q4 2016

Ken Fisher 20,950 sh (unchged)
John Hussman 2,300 sh (unchged)
Paul Tudor Jones Sold Out
Columbia Wanger 686,101 sh (-32.96%)
Jim Simons 385,300 sh (-72.90%)
Joel Greenblatt 12,933 sh (-95.64%)
» More
» Details

Insider Trades

Latest Guru Trades with RMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:COO, NAS:HOLX, OTCPK:OCPNF, NYSE:MTD, NYSE:WAT, OTCPK:TRUMY, OTCPK:SAUHY, NYSE:WST, NAS:XRAY, NYSE:STE, OTCPK:CLPBY, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, NYSE:BCR, NAS:ICUI, NAS:PODD, OTCPK:ANSLY, NYSE:HAE, NYSE:HYH » details
Traded in other countries:RMD.Australia, RME.Germany, RSMDF.USA,
ResMed Inc is a developer, manufacturer and distributor of medical products for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders.

ResMed Inc a Delaware corporation was formed in March, 1994. The Company is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing, or SDB. SDB includes obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep. SDB includes obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep. The Company markets its products in more than 100 countries to sleep clinics, home healthcare dealers and third-party payors. It also markets the products directly to sleep clinics. The Company's portfolio of products include airflow generators, diagnostic products, mask systems, headgear and other accessories. The Company produces CPAP, VPAP and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. The Company's competitors include Philips BV, DeVilbiss Healthcare, Fisher & Paykel Healthcare Corporation Limited, Apex Medical Corporation, BMC Medical Co. Ltd. and regional manufacturers. The Company's products are subject to extensive regulation particularly as to safety, efficacy and adherence to FDA Quality System Regulation, and related manufacturing standards. Medical device products are subject to rigorous FDA and other governmental agency regulations in the United States and similar regulations of foreign agencies abroad.

Ratios

vs
industry
vs
history
PE Ratio 30.24
RMD's PE Ratio is ranked higher than
53% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.87 vs. RMD: 30.24 )
Ranked among companies with meaningful PE Ratio only.
RMD' s PE Ratio Range Over the Past 10 Years
Min: 16.93  Med: 23.5 Max: 66.38
Current: 30.24
16.93
66.38
Forward PE Ratio 24.45
RMD's Forward PE Ratio is ranked lower than
53% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.15 vs. RMD: 24.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.24
RMD's PE Ratio without NRI is ranked higher than
50% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.49 vs. RMD: 30.24 )
Ranked among companies with meaningful PE Ratio without NRI only.
RMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 16.93  Med: 23.47 Max: 64.76
Current: 30.24
16.93
64.76
Price-to-Owner-Earnings 26.85
RMD's Price-to-Owner-Earnings is ranked higher than
51% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.26 vs. RMD: 26.85 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
RMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.88  Med: 23.5 Max: 144.79
Current: 26.85
12.88
144.79
PB Ratio 5.94
RMD's PB Ratio is ranked lower than
77% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.45 vs. RMD: 5.94 )
Ranked among companies with meaningful PB Ratio only.
RMD' s PB Ratio Range Over the Past 10 Years
Min: 2.29  Med: 3.67 Max: 6.86
Current: 5.94
2.29
6.86
PS Ratio 5.16
RMD's PS Ratio is ranked lower than
69% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.96 vs. RMD: 5.16 )
Ranked among companies with meaningful PS Ratio only.
RMD' s PS Ratio Range Over the Past 10 Years
Min: 2.77  Med: 4.48 Max: 6.6
Current: 5.16
2.77
6.6
Price-to-Free-Cash-Flow 24.89
RMD's Price-to-Free-Cash-Flow is ranked higher than
62% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.37 vs. RMD: 24.89 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.35  Med: 24.6 Max: 304.88
Current: 24.89
13.35
304.88
Price-to-Operating-Cash-Flow 21.41
RMD's Price-to-Operating-Cash-Flow is ranked higher than
50% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.55 vs. RMD: 21.41 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.7  Med: 18.68 Max: 44.03
Current: 21.41
10.7
44.03
EV-to-EBIT 24.15
RMD's EV-to-EBIT is ranked higher than
50% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.36 vs. RMD: 24.15 )
Ranked among companies with meaningful EV-to-EBIT only.
RMD' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.8  Med: 17.5 Max: 48.6
Current: 24.15
10.8
48.6
EV-to-EBITDA 19.56
RMD's EV-to-EBITDA is ranked lower than
57% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.65 vs. RMD: 19.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
RMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.5  Med: 14.2 Max: 29.5
Current: 19.56
8.5
29.5
PEG Ratio 3.24
RMD's PEG Ratio is ranked lower than
52% of the 56 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. RMD: 3.24 )
Ranked among companies with meaningful PEG Ratio only.
RMD' s PEG Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.56 Max: 5.05
Current: 3.24
0.7
5.05
Shiller PE Ratio 40.87
RMD's Shiller PE Ratio is ranked higher than
51% of the 47 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 41.26 vs. RMD: 40.87 )
Ranked among companies with meaningful Shiller PE Ratio only.
RMD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 30.9  Med: 42.73 Max: 82.61
Current: 40.87
30.9
82.61
Current Ratio 2.23
RMD's Current Ratio is ranked lower than
56% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.39 vs. RMD: 2.23 )
Ranked among companies with meaningful Current Ratio only.
RMD' s Current Ratio Range Over the Past 10 Years
Min: 0.87  Med: 4.02 Max: 6.44
Current: 2.23
0.87
6.44
Quick Ratio 1.86
RMD's Quick Ratio is ranked higher than
60% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. RMD: 1.86 )
Ranked among companies with meaningful Quick Ratio only.
RMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 3.14 Max: 5.71
Current: 1.86
0.61
5.71
Days Inventory 105.86
RMD's Days Inventory is ranked higher than
64% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.69 vs. RMD: 105.86 )
Ranked among companies with meaningful Days Inventory only.
RMD' s Days Inventory Range Over the Past 10 Years
Min: 100.51  Med: 132.76 Max: 168.51
Current: 105.86
100.51
168.51
Days Sales Outstanding 71.20
RMD's Days Sales Outstanding is ranked lower than
66% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.60 vs. RMD: 71.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.2  Med: 79.69 Max: 85.51
Current: 71.2
71.2
85.51
Days Payable 41.44
RMD's Days Payable is ranked lower than
57% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.38 vs. RMD: 41.44 )
Ranked among companies with meaningful Days Payable only.
RMD' s Days Payable Range Over the Past 10 Years
Min: 36.65  Med: 46.2 Max: 60.16
Current: 41.44
36.65
60.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.80
RMD's Dividend Yield % is ranked higher than
64% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.25 vs. RMD: 1.80 )
Ranked among companies with meaningful Dividend Yield % only.
RMD' s Dividend Yield % Range Over the Past 10 Years
Min: 0.41  Med: 1.88 Max: 2.26
Current: 1.8
0.41
2.26
Dividend Payout Ratio 0.55
RMD's Dividend Payout Ratio is ranked higher than
71% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. RMD: 0.55 )
Ranked among companies with meaningful Dividend Payout Ratio only.
RMD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.44 Max: 0.55
Current: 0.55
0.32
0.55
3-Year Dividend Growth Rate 20.80
RMD's 3-Year Dividend Growth Rate is ranked higher than
67% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.20 vs. RMD: 20.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
RMD' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 20.8
Current: 20.8
0
20.8
Forward Dividend Yield % 1.82
RMD's Forward Dividend Yield % is ranked higher than
63% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. RMD: 1.82 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.80
RMD's 5-Year Yield-on-Cost % is ranked lower than
53% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.99 vs. RMD: 1.80 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
RMD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.41  Med: 1.88 Max: 2.26
Current: 1.8
0.41
2.26
3-Year Average Share Buyback Ratio 0.30
RMD's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.80 vs. RMD: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.6  Med: -2 Max: 2.6
Current: 0.3
-4.6
2.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 26.14
RMD's Price-to-Tangible-Book is ranked lower than
95% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.64 vs. RMD: 26.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.97  Med: 6.19 Max: 34.83
Current: 26.14
2.97
34.83
Price-to-Intrinsic-Value-Projected-FCF 1.78
RMD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. RMD: 1.78 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.35  Med: 2.95 Max: 59.41
Current: 1.78
1.35
59.41
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.07
RMD's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
85% of the 20 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. RMD: 1.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.15
RMD's Price-to-Median-PS-Value is ranked lower than
52% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. RMD: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.05 Max: 2.43
Current: 1.15
0.58
2.43
Price-to-Peter-Lynch-Fair-Value 3.98
RMD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
74% of the 35 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. RMD: 3.98 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
RMD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.73  Med: 1.48 Max: 6.32
Current: 3.98
0.73
6.32
Price-to-Graham-Number 5.92
RMD's Price-to-Graham-Number is ranked lower than
81% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. RMD: 5.92 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.49  Med: 2.79 Max: 14.87
Current: 5.92
1.49
14.87
Earnings Yield (Greenblatt) % 4.13
RMD's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. RMD: 4.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.1  Med: 5.7 Max: 9.3
Current: 4.13
2.1
9.3
Forward Rate of Return (Yacktman) % 10.99
RMD's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.86 vs. RMD: 10.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 10.99  Med: 18.75 Max: 31.1
Current: 10.99
10.99
31.1

More Statistics

Revenue (TTM) (Mil) $1,968
EPS (TTM) $ 2.37
Beta0.74
Short Percentage of Float10.25%
52-Week Range $55.13 - 72.70
Shares Outstanding (Mil)141.66

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 2,095 2,279 1,633
EPS ($) 2.95 3.34 2.22
EPS without NRI ($) 2.95 3.34 2.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.72%
Dividends per Share ($) 1.38 1.54 1.07
» More Articles for NYSE:RMD

Headlines

Articles On GuruFocus.com
Columbia Wanger Boosts LivaNova, Sells Stericycle Aug 19 2016 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
These 7 Growth Stocks Have Potential To Make You Rich Sep 14 2014 
Buy ResMed and Sleep Tight (Like Jim Simons) Feb 02 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Meeting the Herd Mar 25 2013 
The Best Yielding Ex-Dividend Stocks on February 14, 2013 Feb 13 2013 
Weekly CEO Sells Highlight: ResMed Inc., Chuy’s Holdings Inc., Electronics for Imaging Inc., Coher Feb 04 2013 
ResMed - Growing Business with Consistent Cash Flow Generation at Lowest 10-Year Valuation Jan 24 2012 
Weekly CFO Sells Highlight: RMD, CATM, HXL, BCR, AMRC Jul 24 2011 

More From Other Websites
ResMed (RMD) Up 3.6% Since Earnings Report: Can It Continue? Feb 23 2017
ResMed Named Global Leader in Remote Patient Monitoring Feb 13 2017
ResMed Named Global Leader in Remote Patient Monitoring Feb 13 2017
Post Earnings Coverage as ResMed Revenue Increased 17% Jan 30 2017
RESMED INC Financials Jan 28 2017
ETFs with exposure to ResMed, Inc. : January 25, 2017 Jan 25 2017
Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17) Jan 25 2017
ResMed: Cramer's Top Takeaways Jan 25 2017
RESMED INC Files SEC form 10-Q, Quarterly Report Jan 25 2017
Breaking Out: ResMed Stock Launches As Fiscal Q2 Sales, EPS Beat Jan 24 2017
ResMed Reports Q2 Profit of $76.7M (RMD) Jan 24 2017
ResMed, Inc. :RMD-US: Earnings Analysis: Q2, 2017 By the Numbers : January 24, 2017 Jan 24 2017
Morning Movers: Lockheed Martin Tumbles, Johnson & Johnson Slips, AK Steel Soars Jan 24 2017
ResMed (RMD) Beats Earnings and Revenue Estimates in Q2 Jan 24 2017
ResMed upgraded by JP Morgan Jan 24 2017
BlueScope, ResMed news boosts share market Jan 24 2017
ResMed Q2 profit down but revenue up Jan 23 2017
Edited Transcript of RMD earnings conference call or presentation 23-Jan-17 9:30pm GMT Jan 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)